| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Soybean oil does not have a defined biological target as a therapeutic agent. It is a food ingredient and pharmaceutical excipient. The compound is not intended to exert pharmacological effects. Its utility lies in its nutritional properties and its use as a vehicle for drug delivery and as an excipient in pharmaceutical formulations.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for Soybean oil as a pharmacological agent are not documented in the literature, as it is primarily used as a food ingredient and excipient. The oil's fatty acid composition may have biological effects, such as modulation of lipid metabolism and inflammation, but it is not characterized as a pharmacological agent.
|
| ln Vivo |
Soybean oil is not used for in vivo pharmacological activity assessment as a drug compound. It is a food ingredient and pharmaceutical excipient. The compound is not intended to be administered for therapeutic purposes as a drug. Its safety has been evaluated in the context of its use as a food and as an excipient in pharmaceutical formulations.
|
| Enzyme Assay |
Soybean oil is not typically used in enzyme/receptor binding assays as a test compound. Its primary applications are as a food ingredient and as an excipient. When used in research, it may be employed as a vehicle for drug delivery or as a control in studies of lipid metabolism. Standard protocols for lipid analysis are employed for its characterization.
|
| Cell Assay |
Soybean oil is not used in cell-based assays as a test compound. Its primary applications are as a food ingredient and as an excipient. The oil may be used in studies of lipid metabolism or as a component of cell culture media, but it is not characterized as a pharmacological agent for direct cellular effects.
|
| Animal Protocol |
Soybean oil is used in animal studies as a component of diets or as a vehicle for drug delivery. The oil may be administered orally or via injection as a vehicle for lipophilic compounds. Its effects on lipid metabolism, inflammation, and other physiological parameters may be assessed. All procedures must comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
Soybean oil is a complex mixture of triglycerides with a variable fatty acid composition. It is a clear, pale yellow to light amber liquid. The oil is widely used as a cooking oil, food ingredient, and pharmaceutical excipient. It is typically stored under standard laboratory conditions, protected from light and heat to prevent oxidation.
|
| Toxicity/Toxicokinetics |
Soybean oil is generally recognized as safe (GRAS) for use in food products. It is not intended for human therapeutic use as a drug substance. As a research chemical, standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| Additional Infomation |
Soybean oil (CAS#: 8001-22-7) is a vegetable oil extracted from soybeans, composed primarily of triglycerides of linoleic, oleic, palmitic, and linolenic acids. It is used as a cooking oil, food ingredient, and pharmaceutical excipient. This compound is not a drug and is a food ingredient.
|
| CAS # |
8001-22-7
|
|---|---|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.917 g/mL at 25 °C(lit.)
|
| Flash Point |
>230 °F
|
| Index of Refraction |
n20/D 1.4743(lit.)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
